JP2016519132A - アンジオテンシンペプチドによる眼外傷の修復促進 - Google Patents
アンジオテンシンペプチドによる眼外傷の修復促進 Download PDFInfo
- Publication number
- JP2016519132A JP2016519132A JP2016511835A JP2016511835A JP2016519132A JP 2016519132 A JP2016519132 A JP 2016519132A JP 2016511835 A JP2016511835 A JP 2016511835A JP 2016511835 A JP2016511835 A JP 2016511835A JP 2016519132 A JP2016519132 A JP 2016519132A
- Authority
- JP
- Japan
- Prior art keywords
- eye
- corneal
- weight
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000014674 injury Diseases 0.000 title claims abstract description 70
- 230000008733 trauma Effects 0.000 title claims abstract description 56
- 108010064733 Angiotensins Proteins 0.000 title claims abstract description 33
- 230000008439 repair process Effects 0.000 title claims description 8
- 238000000034 method Methods 0.000 claims abstract description 46
- 210000001508 eye Anatomy 0.000 claims description 71
- 238000001356 surgical procedure Methods 0.000 claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 230000035876 healing Effects 0.000 claims description 23
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 22
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 22
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 22
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 22
- 208000027418 Wounds and injury Diseases 0.000 claims description 21
- 230000006378 damage Effects 0.000 claims description 21
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 21
- 230000004054 inflammatory process Effects 0.000 claims description 18
- 230000002980 postoperative effect Effects 0.000 claims description 18
- 206010061218 Inflammation Diseases 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 208000028006 Corneal injury Diseases 0.000 claims description 14
- 206010016654 Fibrosis Diseases 0.000 claims description 13
- 230000004761 fibrosis Effects 0.000 claims description 13
- 208000024891 symptom Diseases 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 11
- 230000001681 protective effect Effects 0.000 claims description 11
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 10
- 206010013774 Dry eye Diseases 0.000 claims description 10
- 210000002159 anterior chamber Anatomy 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 230000004410 intraocular pressure Effects 0.000 claims description 10
- 208000002177 Cataract Diseases 0.000 claims description 9
- 206010030113 Oedema Diseases 0.000 claims description 9
- 239000000607 artificial tear Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 230000004438 eyesight Effects 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 9
- 230000036961 partial effect Effects 0.000 claims description 9
- 208000034693 Laceration Diseases 0.000 claims description 8
- 210000004087 cornea Anatomy 0.000 claims description 8
- 239000003889 eye drop Substances 0.000 claims description 8
- 229940012356 eye drops Drugs 0.000 claims description 8
- 239000000853 adhesive Substances 0.000 claims description 7
- 230000001070 adhesive effect Effects 0.000 claims description 7
- 239000007943 implant Substances 0.000 claims description 7
- 230000035515 penetration Effects 0.000 claims description 7
- 238000002271 resection Methods 0.000 claims description 7
- 239000003190 viscoelastic substance Substances 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- 229940121375 antifungal agent Drugs 0.000 claims description 6
- 239000003429 antifungal agent Substances 0.000 claims description 6
- 239000003443 antiviral agent Substances 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000007906 compression Methods 0.000 claims description 6
- 230000006835 compression Effects 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000000017 hydrogel Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000006072 paste Substances 0.000 claims description 6
- 230000000649 photocoagulation Effects 0.000 claims description 6
- 201000010041 presbyopia Diseases 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 206010015958 Eye pain Diseases 0.000 claims description 5
- 206010023644 Lacrimation increased Diseases 0.000 claims description 5
- 229940035676 analgesics Drugs 0.000 claims description 5
- 239000000730 antalgic agent Substances 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 210000004045 bowman membrane Anatomy 0.000 claims description 5
- 210000003683 corneal stroma Anatomy 0.000 claims description 5
- 238000012937 correction Methods 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 210000001525 retina Anatomy 0.000 claims description 5
- 230000004304 visual acuity Effects 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 230000009610 hypersensitivity Effects 0.000 claims description 4
- 230000004317 lacrimation Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000002207 retinal effect Effects 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 3
- 201000002154 Pterygium Diseases 0.000 claims description 3
- 208000002367 Retinal Perforations Diseases 0.000 claims description 3
- 206010038848 Retinal detachment Diseases 0.000 claims description 3
- 230000001886 ciliary effect Effects 0.000 claims description 3
- 210000002555 descemet membrane Anatomy 0.000 claims description 3
- 230000010339 dilation Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000000871 endothelium corneal Anatomy 0.000 claims description 3
- 210000003560 epithelium corneal Anatomy 0.000 claims description 3
- 239000004519 grease Substances 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 230000007803 itching Effects 0.000 claims description 3
- 208000029233 macular holes Diseases 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 230000036407 pain Effects 0.000 claims description 3
- 230000004264 retinal detachment Effects 0.000 claims description 3
- 229940006076 viscoelastic substance Drugs 0.000 claims description 3
- 206010006784 Burning sensation Diseases 0.000 claims description 2
- 206010015946 Eye irritation Diseases 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 238000002316 cosmetic surgery Methods 0.000 claims description 2
- 231100000013 eye irritation Toxicity 0.000 claims description 2
- 230000002787 reinforcement Effects 0.000 claims description 2
- 230000005945 translocation Effects 0.000 claims description 2
- 238000004904 shortening Methods 0.000 claims 1
- 239000003860 topical agent Substances 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 description 31
- 108090000765 processed proteins & peptides Proteins 0.000 description 28
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 206010023332 keratitis Diseases 0.000 description 7
- 238000013268 sustained release Methods 0.000 description 7
- 239000012730 sustained-release form Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 201000004569 Blindness Diseases 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 201000010666 keratoconjunctivitis Diseases 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 206010070245 Foreign body Diseases 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- RUBMHAHMIJSMHA-LBWFYSSPSA-N aclerastide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)CCCC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 RUBMHAHMIJSMHA-LBWFYSSPSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 229950008138 carmellose Drugs 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 229960003943 hypromellose Drugs 0.000 description 3
- -1 military projectiles Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 229940068984 polyvinyl alcohol Drugs 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 2
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 2
- 241000024188 Andala Species 0.000 description 2
- QMMRCKSBBNJCMR-KMZPNFOHSA-N Angiotensin III Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(C)C)C1=CC=C(O)C=C1 QMMRCKSBBNJCMR-KMZPNFOHSA-N 0.000 description 2
- QSBGWDDCOJYQGY-KOQODJNWSA-N Angiotensin IV Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)C(C)C)C1=CC=C(O)C=C1 QSBGWDDCOJYQGY-KOQODJNWSA-N 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 102400000348 Angiotensin-3 Human genes 0.000 description 2
- 101800000738 Angiotensin-3 Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000006069 Corneal Opacity Diseases 0.000 description 2
- 206010051559 Corneal defect Diseases 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 229960003589 arginine hydrochloride Drugs 0.000 description 2
- 201000009310 astigmatism Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 231100000269 corneal opacity Toxicity 0.000 description 2
- 230000004453 corneal transparency Effects 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- 229960004884 fluconazole Drugs 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 229960004184 ketamine hydrochloride Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229920000024 polymyxin B Polymers 0.000 description 2
- 229960005266 polymyxin b Drugs 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 229960004175 xylazine hydrochloride Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DUEUCUPESSMDMI-VVKHCXNMSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)C(C)C)C1=CC=C(O)C=C1 DUEUCUPESSMDMI-VVKHCXNMSA-N 0.000 description 1
- GXYZOEYEQZDXJK-JPGDYHFISA-N (3s)-3-[[2-[[(2s)-1-[(2s)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-4-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxy-2-phenylethyl]carbamoyl]pyrrolidin-1-yl]-3-(4h-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N GXYZOEYEQZDXJK-JPGDYHFISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 description 1
- QTOZBSNPDCWHPV-UHFFFAOYSA-N 1-ethyl-3-[3-[4-[(5-formyl-4-methoxy-2-phenylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylurea Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C(=NC(OC)=C3C=O)C=3C=CC=CC=3)=CC=2)=C1S(=O)(=O)NC(=O)NCC QTOZBSNPDCWHPV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 101150116411 AGTR2 gene Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102400000349 Angiotensin-4 Human genes 0.000 description 1
- 101800000737 Angiotensin-4 Proteins 0.000 description 1
- 206010070497 Aqueous humour leakage Diseases 0.000 description 1
- PSZNHSNIGMJYOZ-WDSKDSINSA-N Asp-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PSZNHSNIGMJYOZ-WDSKDSINSA-N 0.000 description 1
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 1
- OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 206010011026 Corneal lesion Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 206010053487 Exposure to toxic agent Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- MPZWMIIOPAPAKE-BQBZGAKWSA-N Glu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N MPZWMIIOPAPAKE-BQBZGAKWSA-N 0.000 description 1
- BBBXWRGITSUJPB-YUMQZZPRSA-N Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O BBBXWRGITSUJPB-YUMQZZPRSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- NLPUTBDZNNXHCO-CGHBYZBKSA-N Val(5)-angiotensin II Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 NLPUTBDZNNXHCO-CGHBYZBKSA-N 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 108010027713 angiotensin II (1-8) Proteins 0.000 description 1
- JYPVVOOBQVVUQV-CGHBYZBKSA-N angiotensinamide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 JYPVVOOBQVVUQV-CGHBYZBKSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940097957 dexamethasone 2 mg Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本出願は、2013年4月30日出願の米国特許仮出願第61/817596号 および2014年2月12日出願の同第61/938851号の優先権を主張し、それぞれの全体を参照により本明細書に組み込む。
(a)アンジオテンシンペプチドと;
(b)人工涙液、抗生物質、抗ウイルス剤、抗真菌薬、鎮痛剤および抗炎症薬からなる群から選択される活性薬剤と;
(c)薬学的に許容される担体とを含む医薬組成物を提供する。
R1−R2−R3−R4−R5−R6−R7−R8[配列番号1]
(式中、R1は、H、Asp、Glu、Asn、Acpc(1−アミノシクロペンタンカルボン酸)、Ala、Me2Gly、Pro、Bet、Glu(NH2)、Gly、Asp(NH2)およびSucからなる群から選択されるか、または存在せず;
R2は、Arg、Lys、Ala、Cit、Orn、Ser(Ac)、Sar、D−ArgおよびD−Lysからなる群から選択され;
R3は、Val、Ala、Leu、norLeu、Ile、Gly、Lys、Pro、Aib、AcpcおよびTyrからなる群から選択され;
R4は、Tyr、Tyr(PO3)2、Thr、Ser、homoSer、azaTyrおよびAlaからなる群から選択され;
R5は、Ile、Ala、Leu、norLeu、ValおよびGlyからなる群から選択され;
R6は、His、Argまたは6−NH2−Pheからなる群から選択され;
R7は、ProまたはAlaからなる群から選択され;および
R8は、Phe、Phe(Br)、IleおよびTyrからなる群から選択され、および末端Tyr基としてR4を含む配列を除く)の配列においてR1〜R8基のうちの少なくとも4連続するアミノ酸の配列を含む、または該配列からなる。
R1は、AspおよびGluからなる群から選択されるか、または存在せず;
R2は、Arg、LysおよびAlaからなる群から選択され;
R3は、Val、Ala、Leu、norLeu、Ile、Gly、LysおよびProからなる群から選択され;
R4は、TyrおよびhomoSerからなる群から選択され;
R5は、Ile、Ala、Leu、norLeu、ValおよびGlyからなる群から選択され;
R6は、HisおよびArgからなる群から選択され;
R7は、ProまたはAlaからなる群から選択され;および
R8は、Phe、Ileからなる群から選択されるか、または存在しない。
Asp−Arg−Val−Tyr−Val−His−Pro−Phe 配列番号18
Asn−Arg−Val−Tyr−Val−His−Pro−Phe 配列番号19
Ala−Pro−Gly−Asp−Arg−Ile−Tyr−Val−His−Pro−Phe 配列番号20
Glu−Arg−Val−Tyr−Ile−His−Pro−Phe 配列番号21
Asp−Lys−Val−Tyr−Ile−His−Pro−Phe 配列番号22
Asp−Arg−Ala−Tyr−Ile−His−Pro−Phe 配列番号23
Asp−Arg−Val−Thr−Ile−His−Pro−Phe 配列番号24
Asp−Arg−Val−Tyr−Leu−His−Pro−Phe 配列番号25
Asp−Arg−Val−Tyr−Ile−Arg−Pro−Phe 配列番号26
Asp−Arg−Val−Tyr−Ile−His−Ala−Phe 配列番号27
Asp−Arg−Val−Tyr−Ile−His−Pro−Tyr 配列番号28
Pro−Arg−Val−Tyr−Ile−His−Pro−Phe 配列番号29
Asp−Arg−Pro−Tyr−Ile−His−Pro−Phe 配列番号13
Asp−Arg−Val−Tyr(PO3)2−Ile−His−Pro−Phe 配列番号30
Asp−Arg−norLeu−Tyr−Ile−His−Pro−Phe 配列番号31
Asp−Arg−Val−Tyr−norLeu−His−Pro−Phe 配列番号32
Asp−Arg−Val−homoSer−Tyr−Ile−His−Pro−Phe 配列番号33。
R2−R3−R4−R5−R6−R7−R8[配列番号34]
(式中、R2は、H、Arg、Lys、Ala、Orn、Citron、Ser(Ac)、Sar、D−ArgおよびD−Lysからなる群から選択され;
R3〜R8は、上記で定義した通りであり、および
末端Tyr基としてR4を含む配列を除く)
のものである。
R2−R3−Tyr−R5−His−Pro−Phe[配列番号35]
(式中、R2、R3およびR5は、前述で定義した通りである)
を有する。式Arg−Val−Tyr−Ile−His−Pro−Phe[配列番号2]のアンジオテンシンIIIが特に好ましい。他の好ましい化合物としては、構造Arg−Val−Tyr−Gly−His−Pro−Phe[配列番号36]およびArg−Val−Tyr−Ala−His−Pro−Phe[配列番号37]を有するペプチドが挙げられる。
表1
アミノ酸のための略語
アンジオテンシンII(Ang(1−8)の4,7−環化類似体、もしくは本明細書に開示されるその類似体のいずれか;
アンジオテンシンIII(Ang(2−8))の4,7−環化類似体、もしくは本明細書に開示されるその類似体のいずれか;
アンジオテンシンIV(Ang(3−8))の4,7−環化類似体、もしくは本明細書に開示されるその類似体のいずれか;または
Ang(1−7)の4,7−環化類似体、もしくは本明細書に開示されるその類似体のいずれか。
本発明のすべての態様の別の実施形態において、局所製剤は、重量(mg)/体積(mL)または重量/重量(mg)に基づいて、約0.5%〜約4%のヒドロキシエチルセルロース(HEC)を含む。種々のさらなる実施形態において、局所製剤は、重量(mg)/体積(mL)または重量/重量(mg)に基づいて、約1%〜約3%もしくは約2%のHECを含み得る。
(a)アンジオテンシンペプチドと;
(b)人工涙液(カルメロース、ヒドロキシエチルセルロース、ヒプロメロース、ポリビニルアルコール、サイクロデキストリンなど)、抗生物質(クロラムフェニコール、シプロフロキサシン、ゲンタマイシン、ネオマイシン、ポリミキシンBなど)、抗ウイルス剤(アシクロビルなど)、抗真菌剤(フルコナゾールなど)、鎮痛剤、および抗炎症薬(非ステロイド系抗炎症薬、局所ステロイド、シクロスポリンおよび抗アレルギー薬など)からなる群から選択される活性薬剤と;
(c)薬学的に許容される担体とを含む医薬組成物を提供する。
動物の準備と手法:
追跡検査:
画像診断と組織学:
結果
考察と結論:
Claims (33)
- 眼外傷を治療する方法であって、眼外傷を有する対象に、前記眼外傷を治療するために有効量のアンジオテンシンペプチドを投与することを含む方法。
- 前記眼外傷が外傷、光曝露/放射線曝露もしくは化学曝露、疾患または外科的処置に起因する、請求項1に記載の方法。
- 前記眼外傷が術後炎症、術後線維症、術後の眼圧上昇、角膜損傷、白内障切開、レーザー角膜切削形成術(LASIK)損傷、ドライアイおよびレーザー屈折矯正角膜切除術(PRK)損傷からなる群から選択される損傷を含む、請求項1または2に記載の方法。
- 前記眼外傷が角膜損傷であり、および前記角膜損傷が角膜上皮、角膜内皮、角膜ボーマン膜、デスメ膜および/または角膜実質の前部の穿通を含む、請求項1〜4のいずれか1項に記載の方法。
- 前記角膜損傷が角膜剥離または角膜裂傷を含む、請求項1〜4のいずれか1項に記載の方法。
- 前記治療することが、線維症、炎症、浮腫、眼圧の上昇、眼痛、通常と比べて流涙の増加、霧視、光に対する過敏症、視力の変化および眼に何かが刺さっている感じからなる群から選択される症状の進行および/または重症度を減少させることを含む、請求項4または5に記載の方法。
- 前記治療することが、対照と比較して、角膜治癒および/または前房の形成の時間の短縮を含む、請求項4〜6のいずれか1項に記載の方法。
- 前記眼外傷がドライアイを含む、請求項1〜5のいずれか1項に記載の方法。
- 前記治療することが、眼への刺激、刺すような痛み、充血、砂が入った感じ、かゆさ、灼熱感、眼脂、何かが目に入っている感じ、涙目および霧視からなる群から選択される症状の進行および/または重症度を減少させることを含む、請求項8に記載の方法。
- 前記眼外傷が眼科手術に起因する、請求項1〜7のいずれか1項に記載の方法。
- 前記眼科手術が、角膜曲率形成術、レーザー角膜切削形成術(LASIK)、自動角膜層状切除術(ALK)、レーザー角膜上皮切除術(LASEK)、レーザー屈折矯正角膜切除術(PRK)、レーザー熱角膜形成術(LTK)、伝導式角膜形成術(CK)、角膜輪部減張切開術(LRI)、乱視矯正角膜切開術(AK)、放射状角膜切開術(RK)、ミニ非対称放射状角膜切開術(M.A.R.K.)、六角形角膜切開術(HK)、インプランタブル・コンタクトレンズ、老視回復術、強膜放射状切開術(ACS)、老視のレーザー回復術(LRP)、強膜拡張バンド術、Kamraインレー、強膜補強手術、角膜移植手術、全層角膜移植術(PK)、人工角膜移植術(Kpro)、白内障手術、眼内レンズの挿入、治療的レーザー角膜切除術(PTK)、翼状片切除術、角膜刺青、硝子体切除術、汎網膜光凝固術(PRP)、網膜剥離修復、レーザー光凝固術、気体網膜復位術、網膜冷凍凝固術、黄斑円孔修復、部分的層状強膜切除術、部分的層状強膜毛様体脈絡膜切除術、部分的層状強膜脈絡膜切除術、後強膜切開術、放射状視神経乳頭切開術、黄斑移動術、眼筋手術、眼形成手術、および白内障、緑内障と糖尿病網膜症を治療する手術からなる群から選択される、請求項8に記載の方法。
- 前記治療することが、術後線維症、術後炎症、術後の眼圧の上昇、裂傷、眼脂、穿刺、眼痛、通常と比べて流涙の増加、霧視、光に対する過敏症、視力の変化、および眼に何かが刺さっている感じからなる群から選択される症状の進行および/または重症度を減少させることを含む、請求項1〜11のいずれか1項に記載の方法。
- 前記アンジオテンシンペプチドがNle3−A(1−7)[配列番号14]を含む、請求項1〜12のいずれか1項に記載の方法。
- 前記アンジオテンシンペプチドがNle3−A(1−7)[配列番号14]からなる、請求項1〜12のいずれか1項に記載の方法。
- 前記アンジオテンシンペプチドが、重量(mg)/体積(mL)または重量/重量(mg)に基づいて、約0.01%〜約1%の濃度で投与される、請求項1〜14のいずれか1項に記載の方法。
- 前記アンジオテンシンペプチドが、重量(mg)/体積(mL)または重量/重量(mg)に基づいて、約0.03%〜約3%の濃度で投与される、請求項1〜14のいずれか1項に記載の方法。
- 前記アンジオテンシンペプチドが局所製剤で投与される、請求項1〜16のいずれか1項に記載の方法。
- 前記局所製剤が、ヒドロゲル剤、クリーム剤、粘弾性物質、軟膏、ペースト剤、点眼剤、ナノ粒子剤、ポリマー系製剤およびローション剤からなる群から選択される、請求項16に記載の方法。
- 前記局所製剤が、保護コンタクトレンズ、コンタクトレンズ、円蓋部基底インプラント、眼帯もしくは付着型アイパッチ、圧迫眼帯、および眼球保護帯からなる群から選択される送達補助によって投与される、請求項17〜18のいずれか1項に記載の方法。
- 前記局所製剤が、重量(mg)/体積(mL)または重量/重量(mg)に基づいて、約0.5%〜約4%のヒドロキシエチルセルロース(HEC)を含む、請求項17〜19のいずれか1項に記載の方法。
- 前記局所製剤が、約1%〜約3%のHECを含む、請求項17〜19のいずれか1項に記載の方法。
- 前記方法が、眼外傷を治療するために、人工涙液、抗生物質、抗ウイルス剤、抗真菌薬、鎮痛剤および抗炎症薬からなる群から選択される活性薬剤の有効量を前記対象に投与することをさらに含む、請求項1〜21のいずれか1項に記載の方法。
- 医薬組成物であって、
(a)アンジオテンシンペプチドと;
(b)人工涙液、抗生物質、抗ウイルス剤、抗真菌薬、鎮痛剤および抗炎症薬からなる群から選択される活性薬剤と;
(c)薬学的に許容される担体とを含む医薬組成物。 - 前記活性薬剤が人工涙液を含む、請求項23に記載の医薬組成物。
- 前記アンジオテンシンペプチドが、Nle3−A(1−7)[配列番号14]を含む、請求項23または24に記載の医薬組成物。
- 前記アンジオテンシンペプチドが、Nle3−A(1−7)[配列番号14]からなる、請求項23または24のいずれか1項に記載の医薬組成物。
- 前記アンジオテンシンペプチドが、重量(mg)/体積(mL)または重量/重量(mg)に基づいて、約0.01%〜約1%の濃度で投与される、請求項23〜26のいずれか1項に記載の医薬組成物。
- 前記アンジオテンシンペプチドが、重量(mg)/体積(mL)または重量/重量(mg)に基づいて、約0.03%〜約0.3%の濃度で存在する、請求項23〜27のいずれか1項に記載の医薬組成物。
- 前記医薬組成物が局所製剤として提供される、請求項23〜28のいずれか1項に記載の医薬組成物。
- 前記局所製剤が、ヒドロゲル剤、クリーム剤、粘弾性物質、軟膏、ペースト剤、点眼剤、ナノ粒子剤、ポリマー系製剤およびローション剤からなる群から選択される、請求項29に記載の医薬組成物。
- 前記局所製剤が、保護コンタクトレンズ、コンタクトレンズ、円蓋部基底インプラント、眼帯もしくは付着型アイパッチ、圧迫眼帯、および眼球保護帯からなる群から選択される送達補助上で供給される、請求項29〜30のいずれか1項に記載の医薬組成物。
- 前記局所製剤が、重量(mg)/体積(mL)または重量/重量(mg)に基づいて、約0.5%〜約4%のヒドロキシエチルセルロース(HEC)を含む、請求項29〜31のいずれか1項に記載の医薬組成物。
- 前記局所薬剤が、約1%〜約3%のHECを含む、請求項29〜31のいずれか1項に記載の医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361817596P | 2013-04-30 | 2013-04-30 | |
US61/817,596 | 2013-04-30 | ||
US201461938851P | 2014-02-12 | 2014-02-12 | |
US61/938,851 | 2014-02-12 | ||
PCT/US2014/036128 WO2014179440A1 (en) | 2013-04-30 | 2014-04-30 | Accelerated healing of eye injuries by angiotensin peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016519132A true JP2016519132A (ja) | 2016-06-30 |
JP6472438B2 JP6472438B2 (ja) | 2019-02-20 |
Family
ID=50896533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016511835A Active JP6472438B2 (ja) | 2013-04-30 | 2014-04-30 | アンジオテンシンペプチドによる眼外傷の修復促進 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9844578B2 (ja) |
EP (1) | EP2991663B1 (ja) |
JP (1) | JP6472438B2 (ja) |
CN (1) | CN105377285B (ja) |
AU (1) | AU2014259948B2 (ja) |
CA (1) | CA2909956C (ja) |
ES (1) | ES2650746T3 (ja) |
RU (1) | RU2674148C2 (ja) |
WO (1) | WO2014179440A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2902619A1 (en) | 2013-03-15 | 2014-09-25 | University Of Southern California | Methods for treating multiple sclerosis |
JP6480909B2 (ja) | 2013-03-15 | 2019-03-13 | ユニバーシティー オブ サウザン カリフォルニア | アンギオテンシン関連疾患の処置のための方法、化合物および組成物 |
AU2014284496A1 (en) | 2013-07-03 | 2016-01-21 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method for treating cognitive dysfunction |
US10183055B2 (en) | 2014-07-21 | 2019-01-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications |
WO2016014342A2 (en) | 2014-07-21 | 2016-01-28 | Arizona Board Of Regents For The University Of Arizona | Ang-(1-7) derviative oligopeptides and methods for using and producing the same |
US10987403B2 (en) | 2017-03-10 | 2021-04-27 | University Of Southern California | Cyclodextrin-Nle3-A(1-7) compositions and their use |
RU2676606C1 (ru) * | 2018-02-08 | 2019-01-09 | Христо Периклович Тахчиди | Способ профилактики макулярного разрыва у больных с витреомакулярным тракционным синдромом 1а-1б стадии при наличии макулярного разрыва на парном глазу |
RU2700589C1 (ru) * | 2019-07-05 | 2019-09-18 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) | Способ ускорения заживления роговицы при ее механических травмах |
RU2706715C1 (ru) * | 2019-07-10 | 2019-11-20 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) | Применение раствора оксиэтиламмония метилфеноксиацетата |
WO2023034779A1 (en) * | 2021-08-31 | 2023-03-09 | The Cleveland Clinic Foundation | Topical drug treatment to prevent or reduce corneal scarring |
EP4371556A1 (en) * | 2022-11-15 | 2024-05-22 | Explicat Pharma GmbH | Angiotensin(1-7) pharmaceutical compositions for inhalation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011037868A (ja) * | 2001-11-05 | 2011-02-24 | Univ Federal De Minas Gerais - Ufmg | シクロデキストリン、リポソーム及び生分解性ポリマー並びに/或いはそれらの混合物及び生成物を用いる、ペプチドアンギオテンシン−(1−7)並びにその類似体、作動薬及び拮抗薬の製剤の調製方法 |
JP2011507920A (ja) * | 2007-12-28 | 2011-03-10 | ヘレウス・クルツァ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 皮膚創傷治癒のためのエリスロポエチンの局所適用および製剤 |
WO2012063237A2 (en) * | 2010-11-08 | 2012-05-18 | Healor Ltd. | Buffered ophthalmic compositions and methods of use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5036048A (en) * | 1986-03-07 | 1991-07-30 | Schering Corporation | Angiotensin II receptor blockers as antiglaucoma agents |
JP4347522B2 (ja) * | 1997-12-12 | 2009-10-21 | ユニバーシティ オブ サザン カリフォルニア | 創傷治癒組成物 |
-
2014
- 2014-04-30 ES ES14728744.5T patent/ES2650746T3/es active Active
- 2014-04-30 CA CA2909956A patent/CA2909956C/en active Active
- 2014-04-30 EP EP14728744.5A patent/EP2991663B1/en active Active
- 2014-04-30 US US14/784,251 patent/US9844578B2/en active Active
- 2014-04-30 CN CN201480023406.XA patent/CN105377285B/zh active Active
- 2014-04-30 AU AU2014259948A patent/AU2014259948B2/en active Active
- 2014-04-30 WO PCT/US2014/036128 patent/WO2014179440A1/en active Application Filing
- 2014-04-30 JP JP2016511835A patent/JP6472438B2/ja active Active
- 2014-04-30 RU RU2015144119A patent/RU2674148C2/ru active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011037868A (ja) * | 2001-11-05 | 2011-02-24 | Univ Federal De Minas Gerais - Ufmg | シクロデキストリン、リポソーム及び生分解性ポリマー並びに/或いはそれらの混合物及び生成物を用いる、ペプチドアンギオテンシン−(1−7)並びにその類似体、作動薬及び拮抗薬の製剤の調製方法 |
JP2011507920A (ja) * | 2007-12-28 | 2011-03-10 | ヘレウス・クルツァ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 皮膚創傷治癒のためのエリスロポエチンの局所適用および製剤 |
WO2012063237A2 (en) * | 2010-11-08 | 2012-05-18 | Healor Ltd. | Buffered ophthalmic compositions and methods of use thereof |
Non-Patent Citations (3)
Title |
---|
CURRENT EYE RESEARCH, vol. 31, JPN6018001781, 2006, pages 129 - 136, ISSN: 0003829337 * |
WOUND REPAIR AND REGENERATION, vol. 13, no. 3, JPN6018001780, 2005, pages 309 - 317, ISSN: 0003829336 * |
WOUND REPAIR AND REGENERATION, vol. 9, no. 3, JPN6018001782, 2001, pages 238 - 247, ISSN: 0003829338 * |
Also Published As
Publication number | Publication date |
---|---|
CA2909956A1 (en) | 2014-11-06 |
EP2991663A1 (en) | 2016-03-09 |
EP2991663B1 (en) | 2017-09-13 |
CA2909956C (en) | 2021-06-01 |
JP6472438B2 (ja) | 2019-02-20 |
WO2014179440A1 (en) | 2014-11-06 |
ES2650746T3 (es) | 2018-01-22 |
CN105377285A (zh) | 2016-03-02 |
AU2014259948A1 (en) | 2015-11-05 |
AU2014259948B2 (en) | 2019-04-18 |
US20160051622A1 (en) | 2016-02-25 |
US9844578B2 (en) | 2017-12-19 |
CN105377285B (zh) | 2020-04-21 |
RU2674148C2 (ru) | 2018-12-05 |
RU2015144119A (ru) | 2017-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6472438B2 (ja) | アンジオテンシンペプチドによる眼外傷の修復促進 | |
US5767079A (en) | Method of treating ophthalmic disorders using TGF -β | |
US10881503B2 (en) | Method of corneal transplantation or corneal inlay implantation with cross-linking | |
US20230348534A1 (en) | Sap and peptidomimetics for treatment of eye disease | |
WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
JP2009501727A (ja) | 巨大分子集合体の存在に関連した状態、特に眼科障害の治療 | |
RU2639393C2 (ru) | Состав пролонгированного действия циклоспорина формы 2 | |
CA2138644A1 (en) | Method of treating ophthalmic disorders using tgf-.beta. | |
CN115461040A (zh) | 含有酪氨酸激酶抑制剂的眼用植入物 | |
KR20090040404A (ko) | 고안압증 치료를 위한 항분비 인자의 용도 | |
US20170239330A1 (en) | Formulations for histatin therapeutics | |
CN115066236A (zh) | 糖尿病性黄斑水肿和视敏度受损的治疗 | |
CN1698898A (zh) | 生物降解型眼植入剂 | |
WO2023192691A2 (en) | Methods and formulations for intranasal delivery of insulin in the treatment of diabetic eye disease | |
Everaert | Evaluation of newly developed HPMC ophthalmic inserts with sustained release properties as a carrier for thermolabile therapeutics | |
DK3229780T3 (en) | Ophthalmic composition for use in the treatment of dry eye syndrome | |
US8349005B2 (en) | Method for burying implant to choroid | |
WO2023004124A2 (en) | Histatin combinations and methods for treating or inhibiting cell loss | |
Rodrigues et al. | Retina and ocular toxicity to ocular application of drugs | |
JPH08301785A (ja) | 術後乱視予防剤 | |
US20200179482A1 (en) | Composition for and method of facilitating corneal tissue repair | |
Ayello-Scheer et al. | Temporary Overlay Lyophilized Human Amniotic Membrane Technique for Macular Hole: A Preliminary Study | |
Singla | A Randomized Controlled Prospective Study to Assess the role of Subconjunctival Bevacizumab in Preventing Recurrence in Primary Pterygium Excision |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170425 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180423 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180703 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181003 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181225 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190122 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6472438 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |